6549 Stock Overview
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TaiwanJ Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$12.60 |
| 52 Week High | NT$32.60 |
| 52 Week Low | NT$12.45 |
| Beta | -0.34 |
| 1 Month Change | -8.03% |
| 3 Month Change | -14.86% |
| 1 Year Change | -59.22% |
| 3 Year Change | -13.99% |
| 5 Year Change | -4.98% |
| Change since IPO | -74.80% |
Recent News & Updates
Shareholder Returns
| 6549 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -4.2% | -4.1% | -2.6% |
| 1Y | -59.2% | -26.4% | 25.9% |
Return vs Industry: 6549 underperformed the TW Biotechs industry which returned -26.4% over the past year.
Return vs Market: 6549 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6549 volatility | |
|---|---|
| 6549 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 4.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6549's share price has been volatile over the past 3 months.
Volatility Over Time: 6549's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 12 | Rich Yuan | www.taiwanj.com |
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis.
TaiwanJ Pharmaceuticals Co., Ltd. Fundamentals Summary
| 6549 fundamental statistics | |
|---|---|
| Market cap | NT$946.54m |
| Earnings (TTM) | -NT$6.05m |
| Revenue (TTM) | NT$22.74m |
41.6x
P/S Ratio-156.5x
P/E RatioIs 6549 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6549 income statement (TTM) | |
|---|---|
| Revenue | NT$22.74m |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$22.74m |
| Other Expenses | NT$28.79m |
| Earnings | -NT$6.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -26.59% |
| Debt/Equity Ratio | 0% |
How did 6549 perform over the long term?
See historical performance and comparison